**Table S5.**

1. **Mean (SD) and Median Duration of Morning Joint Stiffness Collected by the Daily Patient Electronic Diaries**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Placebo(N=488)** | **Baricitinib 4 mg QD (N=487)** | **Adalimumab****40 mg Q2W (N=330)** |
| **Day** | **Mean (SD)** | **Median (95%CI of Median Median Difference)** | **Mean (SD)** | **Median (95%CI of Median Median Difference)** | **Mean (SD)** | **Median (95%CI of Median Median Difference)** |
| 1 | 136 (175) | 60 (60, 90) | 166 (181) | 120 (70, 120)\* | 158 (188) | 64 (60, 120) |
| 2 | 133 (156) | 70 (60, 90) | 127 (146) | 60 (60, 90) | 122 (155) | 60 (60, 80) |
| 3 | 132 (159) | 65 (60, 90) | 120 (149) | 60 (60, 80) | 111 (149) | 60 (60, 60)\* |
| 4 | 127 (153) | 60 (60, 90) | 128 (162) | 60 (60, 75)† | 111 (148) | 60 (60, 60)\*\* |
| 5 | 135 (165) | 66 (60, 90) | 121 (158) | 60 (60, 60)\* | 114 (157) | 60 (30, 60)\*\* |
| 6 | 127 (153) | 60 (60, 83) | 120 (155) | 60 (60, 60) † | 104 (142) | 60 (39, 60)\*\* |
| 7 | 131 (162) | 60 (60, 75) | 117 (155) | 60 (60, 60) | 107 (147) | 60 (50, 60)\*\* |
| 8 | 135 (160) | 72 (60, 90) | 109 (147) | 60 (60, 60)\*\* | 101 (142) | 60 (30, 60)\*\*\* |
| 9 | 132 (160) | 60 (60, 90) | 109 (151) | 60 (60, 60)\*\* | 106 (148) | 60 (40, 60)\*\*\* |
| 10 | 127 (157) | 60 (60, 75) |  97 (131) | 60 (60, 60)\*\* | 100 (144) | 60 (40, 60)\*\*\* |
| 11 | 129 (160) | 60 (60, 75) | 102 (140) | 60 (60, 60)\*\* | 107 (148) | 60 (45, 60)\*\* |
| 12 | 133 (160) | 60 (60, 75) | 106 (146) | 60 (60, 60)\*\*\* |  98 (135) | 60 (36, 60)\*\*\* |
| 13 | 132 (159) | 60 (60, 80) | 104 (145) | 60 (60, 60)\*\*\* | 102 (152) | 60 (31, 60)\*\*\* |
| 14 | 133 (163) | 60 (60, 90) | 107 (151) | 60 (60, 60)\*\* | 102 (148) | 60 (31, 60)\*\*\* |
| 15 | 129 (162) | 60 (60, 75) | 107 (152) | 60 (56, 60)\*\* | 109 (163) | 60 (30, 60)\*\* |
| 16 | 123 (156) | 60 (60, 60) | 105 (153) | 60 (40, 60)\*\* | 101 (149) | 60 (30, 60)\*\* |
| 17 | 118 (146) | 60 (60, 65) | 101 (154) | 60 (30, 60)\*\*\* | 102 (152) | 60 (35, 60)\*\* |
| 18 | 122 (151) | 60 (60, 65) | 97 (145) | 60 (40, 60)\*\*\* | 102 (150) | 60 (31, 60)\*\*\* |
| 19 | 120 (155) | 60 (60, 60) | 103 (158) | 60 (35, 60)\*\*\* | 98 (143) | 60 (30, 60)\*\* |
| 20 | 118 (147) | 60 (60, 60) | 101 (150) | 60 (30, 60)\*\*\* | 100 (146) | 60 (30, 60)\*\* |
| 21 | 122 (149) | 60 (60, 80) | 103 (155) | 60 (30, 60)\*\*\* | 103 (150) | 60 (30, 60)\*\*\* |
| 22 | 123 (153) | 60 (60, 60) | 101 (153) | 45 (30, 60)\*\*\* | 104 (151) | 60 (34, 60)\*\* |
| 23 | 124 (158) | 60 (60, 60) | 94 (142) | 45 (30, 60)\*\*\* | 99 (149) | 60 (30, 60)\*\*\* |
| 24 | 117 (143) | 60 (60, 60) | 93 (137) | 45 (30, 60)\*\*\* | 96 (139) | 58 (30, 60)\*\* |
| 25 | 116 (141) | 60 (60, 60) | 98 (143) | 60 (30, 60)\*\*\* | 102 (151) | 60 (30, 60)\*\*\* |
| 26 | 114 (143) | 60 (60, 60) | 95 (144) | 40 (30, 60)\*\*\* | 96 (144) | 60 (30, 60)\*\* |
| 27 | 116 (146) | 60 (60, 60) | 91 (140) | 31 (30, 60)\*\*\* | 102 (152) | 57 (30, 60)\*\* |
| 28 | 116 (147) | 60 (60, 60) | 93 (141) | 37 (30, 60)\*\*\* | 101 (149) | 60 (30, 60)\*\* |

\*p≤0.5, \*\*p ≤0.01, \*\*\*p≤0.001 vs. placebo; †p≤0.5 vs adalimumab

1. **LS Mean Change (95% CI) from baseline for Severity of MJS as Collected by Daily Patient Electronic Diaries**

|  |  |  |  |
| --- | --- | --- | --- |
| **Day** | **Placebo (N=488)****LS Mean (95% CI)** | **Baricitinib 4 mg QD (N=487)****LS Mean (95% CI)** | **Adalimumab****40 mg Q2W (N=330)****LS Mean (95% CI)** |
| 1 | 5.6 (5.3, 5.9) | 6.0 (5.7, 6.3) | 6.0 (5.7, 6.4) |
| 2 | 5.5 (5.3, 5.8) | 5.2 (5.0, 5.5) | 5.0 (4.7, 5.4)\* |
| 3 | 5.4 (5.1, 5.6) | 4.9 (4.6, 5.2)\*\* | 4.8 (4.5, 5.1)\*\* |
| 4 | 5.3 (5.1, 5.6) | 4.8 (4.6, 5.1)\*\* | 4.6 (4.2, 4.9)\*\*\* |
| 5 | 5.3 (5.0, 5.5) | 4.6 (4.4, 4.9)\*\*\* | 4.4 (4.1, 4.7)\*\*\* |
| 6 | 5.2 (5.0, 5.5) | 4.5 (4.3, 4.8)\*\*\* | 4.4 (4.1, 4.7)\*\*\* |
| 7 | 5.2 (5.0, 5.4) | 4.5 (4.2, 4.7)\*\*\* | 4.4 (4.1, 4.7)\*\*\* |
| 8 | 5.1 (4.9, 5.4) | 4.3 (4.1, 4.5)\*\*\* | 4.3 (4.0, 4.5)\*\*\* |
| 9 | 5.1 (4.8, 5.3) | 4.2 (4.0, 4.4)\*\*\* | 4.3 (4.0, 4.5)\*\*\* |
| 10 | 5.0 (4.8, 5.2) | 4.1 (3.9, 4.3)\*\*\* | 4.2 (4.0, 4.5)\*\*\* |
| 11 | 5.0 (4.8, 5.2) | 4.2 (3.9, 4.4)\*\*\* | 4.3 (4.1, 4.6)\*\*\* |
| 12 | 5.1 (4.9, 5.3) | 4.1 (3.9, 4.3)\*\*\* | 4.3 (4.0, 4.5)\*\*\* |
| 13 | 5.0 (4.8, 5.3) | 4.0 (3.8, 4.2)\*\*\* | 4.2 (3.9, 4.4)\*\*\* |
| 14 | 5.0 (4.8, 5.3) | 4.0 (3.8, 4.2)\*\*\* | 4.2 (3.9, 4.5)\*\*\* |
| 15 | 4.8 (4.6, 5.1) | 3.9 (3.7, 4.1)\*\*\* | 4.2 (3.9, 4.4)\*\*\* |
| 16 | 4.8 (4.6, 5.0) | 3.9 (3.7, 4.1)\*\*\* | 4.2 (3.9, 4.4)\*\*\* |
| 17 | 4.8 (4.6, 5.1) | 3.9 (3.7, 4.1)\*\*\* | 4.2 (3.9, 4.4)\*\*\* |
| 18 | 4.8 (4.6, 5.0) | 3.8 (3.6, 4.0)\*\*\* | 4.1 (3.8, 4.3)\*\*\* |
| 19 | 4.8 (4.6, 5.0) | 3.7 (3.5, 4.0)\*\*\*† | 4.1 (3.8, 4.3)\*\*\* |
| 20 | 4.7 (4.5, 4.9) | 3.7 (3.5, 3.9)\*\*\* | 4.0 (3.8, 4.3)\*\*\* |
| 21 | 4.8 (4.6, 5.0) | 3.7 (3.5, 3.9)\*\*\* | 4.0 (3.8, 4.3)\*\*\* |
| 22 | 4.7 (4.5, 4.9) | 3.7 (3.5, 3.9)\*\*\*† | 4.0 (3.8, 4.3)\*\*\* |
| 23 | 4.7 (4.5, 4.9) | 3.7 (3.5, 3.9)\*\*\* | 3.9 (3.7, 4.2)\*\*\* |
| 24 | 4.7 (4.5, 4.9) | 3.6 (3.4, 3.8)\*\*\*† | 4.0 (3.8, 4.2)\*\*\* |
| 25 | 4.7 (4.5, 4.9) | 3.7 (3.5, 3.9)\*\*\* | 4.0 (3.7, 4.2)\*\*\* |
| 26 | 4.6 (4.4, 4.8) | 3.6 (3.4, 3.8)\*\*\* | 3.9 (3.7, 4.1)\*\*\* |
| 27 | 4.7 (4.5, 4.9) | 3.6 (3.4, 3.8)\*\*\*† | 4.0 (3.7, 4.2)\*\*\* |
| 28 | 4.6 (4.4, 4.8) | 3.5 (3.3, 3.7)\*\*\* † | 3.9 (3.7, 4.2)\*\*\* |

\*p≤0.5, \*\*p ≤0.01, \*\*\*p≤0.001 vs. placebo; †p≤0.5 vs adalimumab

**c. LS Mean Change (95% CI) from baseline for Worst Tiredness as Collected by Daily Patient Electronic Diaries**

|  |  |  |  |
| --- | --- | --- | --- |
| **Day** | **Placebo (N=488)****LS Mean (95% CI)** | **Baricitinib 4 mg QD (N=487)****LS Mean (95% CI)** | **Adalimumab****40 mg Q2W (N=330)****LS Mean (95% CI)** |
| 1 | 5.8 (5.5, 6.1) | 6.0 (5.7, 6.3) | 5.9 (5.5, 6.2) |
| 2 | 5.5 (5.2, 5.7) | 5.4 (5.1, 5.6) | 5.2 (4.9, 5.5) |
| 3 | 5.5 (5.2, 5.7) | 5.1 (4.8, 5.3)\* | 4.8 (4.5, 5.1)\*\*\* |
| 4 | 5.3 (5.1, 5.6) | 4.9 (4.7, 5.2)\* | 4.7 (4.4, 5.0)\*\* |
| 5 | 5.2 (5.0, 5.4) | 4.7 (4.5, 5.0)\*\* | 4.6 (4.3, 4.9)\*\* |
| 6 | 5.2 (5.0, 5.4) | 4.6 (4.4, 4.9)\*\*\* | 4.6 (4.3, 4.9)\*\* |
| 7 | 5.2 (5.0, 5.5) | 4.6 (4.4, 4.9)\*\*\* | 4.6 (4.4, 4.9)\*\* |
| 8 | 5.2 (5.0, 5.5) | 4.5 (4.3, 4.8)\*\*\* | 4.6 (4.3, 4.9)\*\*\* |
| 9 | 5.2 (5.0, 5.5) | 4.5 (4.3, 4.8)\*\*\* | 4.6 (4.3, 4.8)\*\*\* |
| 10 | 5.1 (4.9, 5.3) | 4.4 (4.2, 4.6)\*\*\* | 4.6 (4.3, 4.8)\*\*\* |
| 11 | 5.1 (4.9, 5.3) | 4.4 (4.2, 4.6)\*\*\* | 4.7 (4.4, 4.9)\*\* |
| 12 | 5.2 (5.0, 5.4) | 4.4 (4.2, 4.6)\*\*\* | 4.6 (4.3, 4.9)\*\*\* |
| 13 | 5.1 (4.8, 5.3) | 4.3 (4.1, 4.5)\*\*\* | 4.5 (4.3, 4.8)\*\* |
| 14 | 5.1 (4.9, 5.3) | 4.3 (4.1, 4.5)\*\*\* | 4.5 (4.3, 4.8)\*\*\* |
| 15 | 5.1 (4.9, 5.3) | 4.4 (4.2, 4.6)\*\*\* | 4.5 (4.2, 4.7)\*\*\* |
| 16 | 4.9 (4.7, 5.1) | 4.3 (4.1, 4.5)\*\*\* | 4.5 (4.3, 4.8)\* |
| 17 | 5.0 (4.8, 5.2) | 4.2 (4.0, 4.5)\*\*\* | 4.5 (4.3, 4.7)\*\* |
| 18 | 4.9 (4.7, 5.1) | 4.2 (4.0, 4.4)\*\*\* | 4.4 (4.1, 4.6)\*\* |
| 19 | 4.9 (4.7, 5.1) | 4.2 (4.0, 4.4)\*\*\* | 4.4 (4.2, 4.6)\*\* |
| 20 | 4.9 (4.7, 5.1) | 4.2 (4.0, 4.4)\*\*\* | 4.4 (4.1, 4.6)\*\* |
| 21 | 4.9 (4.7, 5.1) | 4.1 (3.9, 4.3)\*\*\*† | 4.4 (4.2, 4.6)\*\* |
| 22 | 4.9 (4.7, 5.1) | 4.2 (4.0, 4.4)\*\*\* | 4.3 (4.1, 4.5)\*\*\* |
| 23 | 4.8 (4.6, 5.0) | 4.1 (3.9, 4.3)\*\*\* | 4.3 (4.1, 4.5)\*\*\* |
| 24 | 4.8 (4.6, 5.0) | 4.1 (3.9, 4.3)\*\*\* | 4.3 (4.1, 4.6)\*\* |
| 25 | 4.8 (4.6, 5.0) | 4.1 (3.9, 4.3)\*\*\* | 4.3 (4.1, 4.5)\*\*\* |
| 26 | 4.9 (4.7, 5.1) | 4.1 (3.9, 4.3)\*\*\* | 4.3 (4.0, 4.5)\*\*\* |
| 27 | 4.8 (4.6, 5.0) | 4.0 (3.8, 4.2)\*\*\* | 4.2 (4.0, 4.4)\*\*\* |
| 28 | 4.8 (4.6, 5.0) | 4.0 (3.8, 4.2)\*\*\*† | 4.4 (4.1, 4.6)\*\* |

\*p≤0.5, \*\*p ≤0.01, \*\*\*p≤0.001 vs. placebo; †p≤0.5 vs adalimumab

1. **LS Mean Change (95% CI) from baseline for Worst Joint Pain as Collected by Daily Patient Electronic Diaries**

|  |  |  |  |
| --- | --- | --- | --- |
| **Day** | **Placebo (N=488)****LS Mean (95% CI)** | **Baricitinib 4 mg QD (N=487)****LS Mean (95% CI)** | **Adalimumab****40 mg Q2W (N=330)****LS Mean (95% CI)** |
| 1 | 6.0 (5.8, 6.3) | 6.5 (6.2, 6.8)\* | 6.1 (5.8, 6.5) |
| 2 | 5.8 (5.6, 6.1) | 5.6 (5.4, 5.9) | 5.4 (5.1, 5.7) |
| 3 | 5.7 (5.5, 6.0) | 5.2 (5.0, 5.5)\*\* | 5.0 (4.7, 5.3)\*\*\* |
| 4 | 5.6 (5.3, 5.8) | 5.1 (4.8, 5.3)\*\* | 4.8 (4.5, 5.1)\*\*\* |
| 5 | 5.6 (5.4, 5.9) | 4.9 (4.7, 5.1)\*\*\* | 4.8 (4.5, 5.1)\*\*\* |
| 6 | 5.5 (5.3, 5.8) | 4.8 (4.6, 5.1)\*\*\* | 4.8 (4.5, 5.1)\*\*\* |
| 7 | 5.5 (5.3, 5.7) | 4.9 (4.6, 5.1)\*\*\* | 4.8 (4.5, 5.1)\*\*\* |
| 8 | 5.5 (5.2, 5.7) | 4.7 (4.5, 4.9)\*\*\* | 4.8 (4.5, 5.0)\*\*\* |
| 9 | 5.5 (5.3, 5.7) | 4.7 (4.4, 4.9)\*\*\* | 4.6 (4.4, 4.9)\*\*\* |
| 10 | 5.5 (5.3, 5.7) | 4.5 (4.3, 4.7)\*\*\* | 4.7 (4.4, 4.9)\*\*\* |
| 11 | 5.3 (5.1, 5.5) | 4.6 (4.4, 4.8)\*\*\* | 4.8 (4.5, 5.0)\*\*\* |
| 12 | 5.5 (5.3, 5.7) | 4.5 (4.3, 4.8)\*\*\* | 4.7 (4.5, 5.0)\*\*\* |
| 13 | 5.4 (5.2, 5.6) | 4.4 (4.2, 4.6)\*\*\* | 4.7 (4.4, 4.9)\*\*\* |
| 14 | 5.4 (5.2, 5.6) | 4.5 (4.3, 4.7)\*\*\* | 4.6 (4.4, 4.9)\*\*\* |
| 15 | 5.2 (5.0, 5.4) | 4.4 (4.2, 4.6)\*\*\* | 4.6 (4.3, 4.8)\*\*\* |
| 16 | 5.2 (5.0, 5.4) | 4.4 (4.2, 4.6)\*\*\* | 4.6 (4.4, 4.9)\*\*\* |
| 17 | 5.3 (5.1, 5.5) | 4.2 (4.0, 4.4)\*\*\*†† | 4.6 (4.4, 4.9)\*\*\* |
| 18 | 5.2 (5.0, 5.4) | 4.3 (4.1, 4.5)\*\*\* | 4.5 (4.3, 4.8)\*\*\* |
| 19 | 5.1 (4.9, 5.3) | 4.2 (4.0, 4.4)\*\*\*† | 4.5 (4.3, 4.8)\*\*\* |
| 20 | 5.1 (4.9, 5.3) | 4.2 (4.0, 4.4) \*\*\*† | 4.6 (4.3, 4.8)\*\*\* |
| 21 | 5.2 (5.0, 5.4) | 4.2 (4.0, 4.4) \*\*\*† | 4.5 (4.2, 4.7)\*\*\* |
| 22 | 5.1 (5.0, 5.3) | 4.1 (3.9, 4.3) \*\*\*† | 4.5 (4.3, 4.7)\*\*\* |
| 23 | 5.1 (4.9, 5.3) | 4.1 (4.0, 4.3)\*\*\* | 4.4 (4.2, 4.6)\*\*\* |
| 24 | 5.1 (4.9, 5.3) | 4.1 (3.9, 4.3) \*\*\*† | 4.5 (4.2, 4.7)\*\*\* |
| 25 | 5.1 (4.9, 5.3) | 4.2 (4.0, 4.4)\*\*\* | 4.4 (4.2, 4.6)\*\*\* |
| 26 | 5.1 (4.9, 5.3) | 4.1 (3.9, 4.2)\*\*\* | 4.3 (4.1, 4.5)\*\*\* |
| 27 | 5.1 (4.9, 5.3) | 4.0 (3.8, 4.2) \*\*\*† | 4.3 (4.1, 4.6)\*\*\* |
| 28 | 5.0 (4.8, 5.2) | 3.9 (3.7, 4.1) \*\*\*††† | 4.4 (4.2, 4.7)\*\*\* |

 \*p≤0.5, \*\*p ≤0.01, \*\*\*p≤0.001 vs. placebo; †p≤0.5, ††p≤0.01, †††p≤0.001 vs adalimumab